– Reuters Citing Conf Call
Needham Maintains Buy on Harmony Biosciences, Raises Price Target to $65
Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $60 to $65.
Related Posts
DA Davidson Initiates Coverage On Microsoft with Buy Rating, Announces Price Target of $270
DA Davidson analyst Gil Luria initiates coverage on Microsoft (NASDAQ:MSFT) with a Buy rating and announces Price Target of $270.
Cathie Wood’s Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units
On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units.
Barclays Maintains Overweight on Patterson-UTI Energy, Raises Price Target to $24
Barclays analyst David Anderson maintains Patterson-UTI Energy (NASDAQ:PTEN) with a Overweight and raises the price target from $20 to $24.